NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. announced today that it has appointed Frank Murdolo, Vice President - Investor Relations.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO)
Mr. Murdolo joins Forest following eleven years with GlaxoSmithKline PLC where he was Vice President of Investor Relations, with overall responsibility for managing the North American investor relations program. Prior to joining GSK, he worked for the Schering-Plough Corporation as the Director of Investor Relations for six years and earlier in roles of increasing responsibility within the Schering Finance organization.
Frank Perier, Jr., Forest's Senior Vice President - Finance and Chief Financial Officer, commented: "We are very pleased to have a person with Frank Murdolo's extensive experience with both the financial community and the pharmaceutical industry join Forest as the Company's principal external spokesperson. As the Company continues to grow and build its pipeline of products for the future, Frank's knowledge, experience and reputation will be of great value to the Company and its investors."
About Forest Laboratories
Forest Laboratories is a US-based pharmaceutical company with a long track record of building partnerships and developing and delivering products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.
Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.
CONTACT: Frank Murdolo, Vice President - Investor Relations, Forest
Laboratories, Inc., +1-212-224-6714, Frank.Murdolo@frx.com
Web site: http://www.frx.com/
